Valuation: Proteomics International Laboratories Ltd

Market Cap 19M 13.33M 11.59M 10.79M 9.91M 18.71M 1.27B 127M 49.91M 634M 50.08M 48.98M 2.12B P/E 2024
-17.4x
P/E 2025 -5.38x
Enterprise Value 8.24M 5.78M 5.03M 4.68M 4.3M 8.11M 552M 55.15M 21.64M 275M 21.71M 21.24M 921M EV / Sales 2024
33.2x
EV / Sales 2025 12.8x
Free-Float
74.56%
Yield 2024 *
-
Yield 2025 -
1 week-6.45%
1 month+3.57%
3 months-42.00%
6 months-69.15%
Current year-77.86%
1 week 0.14
Extreme 0.145
0.18
1 month 0.14
Extreme 0.145
0.22
Current year 0.1
Extreme 0.098
0.86
1 year 0.1
Extreme 0.098
0.86
3 years 0.1
Extreme 0.098
1.4
5 years 0.1
Extreme 0.098
1.4
10 years 0.1
Extreme 0.098
1.48
Manager TitleAgeSince
Chief Executive Officer - 19/01/2026
Director of Finance/CFO - 17/04/2026
Director of Finance/CFO - 12/07/2021
Director TitleAgeSince
Director/Board Member - 22/11/2017
Chairman 56 -
Director/Board Member - 08/11/2024
Date Insider Type Main position Quantity % Market Cap.
21/11/24 Free

Founder

800,000 0.6107%
21/11/24 Free

Founder

800,000 0.6107%
21/11/24 Free

Founder

1,000,000 0.7633%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-6.45%-59.72%-82.32% 16.81M
+2.35%+2.74%+38.10%+71.29% 56.54B
-0.21%-7.38%+27.52%+61.15% 53.6B
-2.44%+1.40%-15.61%-15.45% 22.91B
-2.85%-7.78%-9.28%+345.55% 21.37B
+2.49%-0.92%+23.57%-13.14% 20.27B
+0.79%-1.06%+33.99%-31.95% 17.56B
+0.58%-5.88%+19.40%+527.50% 14.75B
+3.41%-6.61%+162.81%+278.22% 13.53B
-5.25%-4.23%+42.32%+170.15% 13.33B
Average -0.11%-4.06%+26.31%+131.10% 23.39B
Weighted average by Cap. +0.23%-2.96%+30.79%+116.82%

Financials

2024 2025
Net sales 3.28M 2.3M 2M 1.86M 1.71M 3.23M 220M 21.93M 8.61M 109M 8.64M 8.45M 366M 3.31M 2.33M 2.02M 1.88M 1.73M 3.26M 222M 22.18M 8.7M 111M 8.73M 8.54M 371M
Net income -6.38M -4.48M -3.89M -3.62M -3.32M -6.28M -427M -42.69M -16.75M -213M -16.81M -16.44M -713M -8.11M -5.7M -4.95M -4.61M -4.23M -7.99M -544M -54.33M -21.32M -271M -21.39M -20.92M -908M
Net Debt -6.32M -4.44M -3.86M -3.59M -3.3M -6.23M -424M -42.34M -16.62M -211M -16.67M -16.31M -707M -10.76M -7.55M -6.57M -6.11M -5.61M -10.59M -721M -72.03M -28.27M -359M -28.36M -27.74M -1.2B
Logo Proteomics International Laboratories Ltd
Proteomics International Laboratories Ltd is an Australia-based medical technology company. The Company is engaged in predictive diagnostics and bioanalytical services. It specializes in the area of proteomics, the industrial scale study of the structure and function of proteins. It focuses on developing and commercializing diagnostic tests for chronic diseases. Its principal activities fall into three key areas: commercialization of PromarkerD, the predictive test for diabetic kidney disease (DKD) and future kidney function decline in patients with type 2 diabetes; precision diagnostic tests in development: the Promarker pipeline, and specialist accredited analytical services on a commercial basis. Its Promarker pipeline and analytical services include PromarkerEndo, PromarkerEso and OxiDx technology. PromarkerEndo is a prototype diagnostic test for endometriosis identifying up to 90% of patients with the disease. PromarkerEso is a prototype diagnostic test for esophageal cancer.
Employees
-
Date Price Change Volume
31/07/26 A$0.1450 -.--% 31,370
30/07/26 A$0.1450 -3.33% 82,425
29/07/26 A$0.1500 -3.23% 47,228
28/07/26 A$0.1550 -3.13% 206,888
27/07/26 A$0.1600 +3.23% 311,763

Annual profits - Rate of surprise